Skip to main content
. 2017 Apr 12;6(5):944–952. doi: 10.1002/cam4.1058

Table 1.

Clinical and smoking characteristics of lung cancer patients with brain metastases receiving intracranial stereotactic radiosurgery stratified by histology (N = 366)

Adenocarinoma Nonadenocarcinoma P
n = 218 n = 148
Age (median [range]) 63.00 [31.00, 87.00] 64.00 [33.00, 88.00] 0.53
Male gender (%) 120 (55) 79 (53) 0.84
Number of brain metastases (%) 0.22
1 106 (49) 83 (56)
2 45 (21) 34 (23)
3 34 (16) 17 (12)
4 +  33 (15) 14 (9.5)
Systemic disease burden (%) 0.52
None 49 (23) 31 (21)
Oligometastatic 107 (49) 80 (54)
Unknown 4 (1.8) 5 (3.4)
Widespread 58 (27) 32 (22)
Systemic disease status (%) 0.40
Progressive 71 (33) 44 (30)
Stable 132 (61) 88 (60)
Unknown 15 (6.9) 16 (11)
KPS (%) 0.30
50 1 (0.50) 0 (0.0)
60 14 (6.4) 16 (11)
70 34 (16) 18 (12)
80 96 (44) 69 (47)
90 69 (32) 39 (26)
100 4 (1.8) 6 (4.1)
DSGPA (%) 0.47
0 3 (1.4) 0 (0.0)
0.5 9 (4.1) 10 (6.8)
1 41 (19) 28 (19)
1.5 65 (30) 41 (28)
2 37 (17) 29 (20)
2.5 34 (16) 23 (16)
3 22 (10) 9 (6.1)
3.5 6 (2.8) 8 (5.4)
4 1 (0.50) 0 (0.0)
Smoking Status (%) 0.40
Current 77 (36) 60 (41)
Noncurrent 135 (62) 88 (59)
Unknown 2 (0.90) 0 (0.0)
Pack years (median [IQR]) 40 [20, 50] 40 [20, 50] 0.60
Metastasis number (median [range]) 2.00 [1.00, 13.00] 1.00 [1.00, 18.00] 0.074
Minimal_dose (median [range]) 20.00 [11.00, 24.00] 20.00 [10.00, 24.00] 0.71

KPS, Karnofsky performance status; DS‐GPA, disease‐specific Graded Prognostic Assessment.